Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating IBI363 monotherapy versus pembrolizumab for unresectable locally advanced or metastatic mucosal or acral melanoma in patients who have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Melanoma
• Melanoma
• Mucosal Melanoma

Drugs mentioned

• IBI363
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Melanoma | Phase 2 | Status: RECRUITING